Peptides · Peptide comparison
Exenatide vs Semaglutide
First-in-class GLP-1 receptor agonist derived from Gila monster venom (Byetta/Bydureon), FDA-approved for type 2 diabetes with demonstrated cardiovascular safety in the 14,752-patient EXSCEL trial and available in both twice-daily and once-weekly formulations
The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.
- Weight Management
- Weight Management
At a glance
Quick comparison
Efficacy
Benefit ratings
Blood Sugar Control
Weight Loss
Heart Safety
Appetite Control
Heart Protection
Technical data
Compound specifications
Exenatide
- Molecular formula
- C184H282N50O60S
- Molecular weight
- 4,187 Da
- Half-life
- Byetta: ~2.4 hours (immediate-release); Bydureon: ~7 weeks effective duration via PLGA microsphere technology; Tmax ~2.1 hours (Byetta)
- Bioavailability
- 65–75% after subcutaneous injection (Byetta); microsphere sustained release for Bydureon
- CAS number
- 183321-74-6
Semaglutide
- Molecular formula
- C187H291N45O59
- Molecular weight
- 4113.58 g/mol
- Half-life
- Approximately 7 days (168 hours)
- Bioavailability
- 89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)
- CAS number
- 910463-68-2
Protocols
Dosing compared
Exenatide
Subcutaneous
- 5 mcgTwice daily, within 60 minutes before the two main meals · First 1 monthFDA-labeled starting dose for immediate-release Byetta to assess tolerability before escalating [6].
- 10 mcgTwice daily, within 60 minutes before the two main meals · OngoingFDA-labeled maintenance dose for immediate-release Byetta after 1 month at the starting dose [6].
- 2 mgOnce weekly · Ongoing chronic therapyExtended-release exenatide (Bydureon) FDA-labeled at 2 mg once every 7 days; convenient weekly alternative to twice-daily dosing [7]. Once-weekly exenatide has cardiovascular outcome data [1].
Semaglutide
Subcutaneous
- 4 weeks0.25 mgOnce weekly · 4 weeksThis is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up [5].
- At least 4 weeks at each step0.5-1 mgOnce weekly · At least 4 weeks at each stepAfter the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase [5].
- Ongoing/maintenance2-2.4 mgOnce weekly · Ongoing/maintenanceThe highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) [5]; up to 2.4 mg is used for weight management (Wegovy) after a slower titration.
Oral
- 30 days3 mgOnce daily · 30 daysThe pill form (Rybelsus) starts at 3 mg each morning for 30 days. Like the starter shot, this dose is for getting started and does not control blood sugar by itself. Take on an empty stomach with a small sip of water, 30 minutes before food or other pills [6].
- 30+ days7 mgOnce daily · 30+ daysAfter the first 30 days, the dose increases to 7 mg once daily. This is the first dose that actively lowers blood sugar [6].
- Ongoing/maintenance14 mgOnce daily · Ongoing/maintenanceThe highest pill dose, used if more blood sugar control is needed after at least 30 days at 7 mg [6].
Applications
Best suited for
Exenatide
- Type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit
- Exenatide is particularly well-suited for individuals focused on type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
- Patients preferring once-weekly dosing convenience (Bydureon 2 mg) over daily injections for improved adherence
- Exenatide is particularly well-suited for individuals focused on patients preferring once-weekly dosing convenience (bydureon 2 mg) over daily injections for improved adherence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
- Overweight or obese type 2 diabetes patients (BMI >27) requiring glycemic control without weight gain
- Exenatide is particularly well-suited for individuals focused on overweight or obese type 2 diabetes patients (bmi >27) requiring glycemic control without weight gain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [4].
- Patients with established cardiovascular disease who need a GLP-1 RA with demonstrated cardiovascular safety
- Exenatide is particularly well-suited for individuals focused on patients with established cardiovascular disease who need a glp-1 ra with demonstrated cardiovascular safety. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Semaglutide
- People with Obesity Seeking Significant Weight Loss
- If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. [7] Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds [1].
- Those Who've Struggled with Diet and Exercise Alone
- Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less [3][7][13].
- People with Type 2 Diabetes Needing Better Control
- Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. [3][5] It can often allow people to reduce or eliminate other diabetes medications [21].
- Individuals at High Cardiovascular Risk
- The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes [2].
Safety profile
Side effects
Exenatide
Common
- Nausea
- Vomiting and diarrhea
- Injection site nodules (Bydureon)
- Decreased appetite and constipation
Uncommon
- Hypoglycemia
Serious
- Acute pancreatitis
- Renal impairment
Semaglutide
Common
- Nausea
- Constipation or Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Loss (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Research status
Safety & evidence
Exenatide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Exenatide is an FDA-approved GLP-1 receptor agonist with post-market safety data spanning 15+ years, though some safety concerns have emerged. Nausea affects 30-45% of patients, [6] dose-dependent and typically improves within 1-2 weeks but can lead to treatment discontinuation in 5% of patients. Pancreatitis risk, while rare (0.1-0.2%), is increased and contraindicated in patients with history of acute pancreatitis. Benign thyroid C-cell adenomas were seen in rats across all exenatide doses in a 104-week carcinogenicity study, but this appears only in the Nonclinical Toxicology section: the immediate-release label (Byetta) carries no boxed warning and does not contraindicate medullary thyroid cancer or MEN 2. That contraindication belonged to extended-release Bydureon, which no longer has a current US label. Acute kidney injury has been reported in 0.3-1% of patients, particularly with concurrent NSAID or ACE inhibitor use. Hypoglycemia risk is minimal when used as monotherapy but increases substantially when combined with insulin or sulfonylureas.
Contraindications
- Prior serious hypersensitivity reaction to exenatide or any excipient [6]
- Extended-release exenatide only (Bydureon, now withdrawn in the US): personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. The immediate-release label carries no such contraindication and no boxed warning [6][7].
Semaglutide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. [1][2][8][9][10] The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. [1][7] The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss [2].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [7]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [7]
- History of serious allergic reaction to semaglutide [7]
Decision guide
Which is right for you?
Exenatide
Choose Exenatide if…
- Type 2 diabetes patients inadequately controlled on metformin seeking add-on therapy with weight loss benefit
- Patients preferring once-weekly dosing convenience (Bydureon 2 mg) over daily injections for improved adherence
- Overweight or obese type 2 diabetes patients (BMI >27) requiring glycemic control without weight gain
- Patients with established cardiovascular disease who need a GLP-1 RA with demonstrated cardiovascular safety
Semaglutide
Choose Semaglutide if…
- Significant weight loss
- Long-term weight management
- Cardiovascular risk reduction
- Blood sugar control